

Compose

Inbox 4,860

★ Starred

🕒 Snoozed

📌 Important

➤ Sent

📧 Drafts 113

Meet

📺 New meeting

🗣️ Join a meeting

Hangouts

R Resti - +

No recent chats
[Start a new one](#)

Fwd: Your submission to BMC Infectious Diseases - INFD-D-19-02234

Inbox x

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yohko

Feb 11, 2020, 5:59 AM



----- Forwarded Message -----

Subject:Your submission to BMC Infectious Diseases - INFD-D-19-02234**Date:**11 Feb 2020 08:20:25 -0500**From:**BMC Infectious Diseases Editorial Office <em@editorialmanager.com>**Reply-To:**BMC Infectious Diseases Editorial Office <marielette.costoy@springer.com>**To:**Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234

Potential therapeutic role of bone marrow-derived mesenchymal stem cells in acute lung injury caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice

Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc; Jezzy R Dewantari, B.Sc; Aldise M Nastri, M.Sc; Emmanuel D Poetranto, Ph.D; Laksmi Wulandari1, Ph.D; Maria I Lusida, MD, Ph.D; Soetjpto Soetjpto, MD, Ph.D; Gatot Soegiarto, MD. Ph.D; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu

BMC Infectious Diseases

Dear Dr. Shimizu,

Thank you for submitting your manuscript, "Potential therapeutic role of bone marrow-derived mesenchymal stem cells in acute lung injury caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice" (INFD-D-19-02234), to BMC Infectious Diseases.

As per our discussion, please upload the most recent version of your manuscript before we send it for peer-review.

Please submit your revised manuscript by accessing the following site:

<https://www.editorialmanager.com/infd/>If you have forgotten your password, please use the 'Send Login Details' link on the login page at <https://www.editorialmanager.com/infd/>. For security reasons, your password will be reset.Please note, if your manuscript is accepted you will not be able to make any changes to the authors, or order of authors, of your manuscript once the editor has accepted your manuscript for publication. If you wish to make any changes to authorship before you resubmit your revisions, please reply to this email and ask for a 'Request for change in authorship' form which should be completed by all authors (including those to be removed) and returned to this email address. Please ensure that any changes in authorship fulfil the criteria for authorship as outlined in BioMed Central's editorial policies (<http://www.biomedcentral.com/about/editorialpolicies#authorship>).

Once you have completed and returned the form, your request will be considered and you will be advised whether the requested changes will be allowed.

By resubmitting your manuscript you confirm that all author details on the revised version are correct, that all authors have agreed to authorship and order of authorship for this manuscript and that all authors have the appropriate permissions and rights to the reported data.

Please be aware that we may investigate, or ask your institute to investigate, any unauthorised attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript before 25 Feb 2020.

Best wishes,

Leanne Archer
BMC Infectious Diseases
<https://bmcinfectdis.biomedcentral.com/>If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (http://bit.ly/NRES_BS) and American Journal Experts (http://bit.ly/AJE_BS) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial (<https://www.springer.com/gb/authors-editors/authorandreviewertutorials/writinginenglish>) and our Writing resources (<http://www.biomedcentral.com/getpublished/writing-resources>). These cover common mistakes that occur when writing in English.-----
Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements this will cause a delay whilst the issue is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all submissions to BMC Infectious Diseases must have a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (<https://bmcinfectdis.biomedcentral.com/>).

Where a mandatory section is not relevant to your study design or article type, for example, if your manuscript does not contain any individual persons data, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must state that data will not be shared, and provide reasons for this in the manuscript text. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page - <http://www.biomedcentral.com/submissions/editorial-policies#availability-of-data-and-materials>.

Declarations

- Ethics approval and consent to participate
- Consent to publish
- Availability of data and materials
- Competing interests
- Funding
- Authors' Contributions
- Acknowledgements
- Authors' Information

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/infid/login.asp?a=r>). Please contact the publication office if you have any questions.

Congratulations!

Great!

Good news!

Reply

Reply all

Forward

Gmail interface showing an email from Shinzu Kazufumi to Dr. Restani. The email subject is 'Fwd: Your submission to BMC Infectious Diseases - INF-D-19-02234R1'. The body contains a decision letter from the journal editor, detailing the review process, reviewer comments, and instructions for the author to revise the manuscript. The letter is signed by Editor Polinski and includes a disclaimer about the journal's policies and the confidentiality of the submission.

Compose

Inbox 4,860

Starred

Snoozed

Important

Sent

Meet

New meeting

Join a meeting

Hangouts

Resti - +

No recent chats

Start a new one

Fwd: Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R2

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yohko

Sat, May 30, 2020, 9:55 AM

----- Forwarded Message -----

Subject:Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R2
Date:30 May 2020 12:51:33 -0400
From:BMC Infectious Diseases Editorial Office <em@editorialmanager.com>
Reply-To:BMC Infectious Diseases Editorial Office <marielette.costoy@springer.com>
To:Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R2

Potential therapeutic role of bone marrow-derived mesenchymal stem cells in acute lung injury caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice

Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc; Jezzy R Dewantari, B.Sc; Aldise M Nastri, M.Sc; Emmanuel D Poetranto, Ph.D; Laksmi Wulandari1, Ph.D; Maria I Lusida, MD, Ph.D; Soetjpto Soetjpto, MD, Ph.D; Gatot Soegiarto, MD. Ph.D; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu
BMC Infectious Diseases

Dear Dr. Shimizu,

Thank you for the revised version of your manuscript 'Potential therapeutic role of bone marrow-derived mesenchymal stem cells in acute lung injury caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice' submitted to BMC Infectious Diseases.

You may check the status of your manuscript at any time by accessing the following website:

<https://www.editorialmanager.com/infid/>

If you have forgotten your password, please use the 'Send Login Details' link on the login page at <https://www.editorialmanager.com/infid/>. For security reasons, your password will be reset.

We will inform you of the Editor's decision as soon as possible.

Best wishes,

Editorial Office
BMC Infectious Diseases
<https://bmcinfectdis.biomedcentral.com/>

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/infid/login.asp?a=r>). Please contact the publication office if you have any questions.



Reply

Reply all

Forward

shimizu.kazufumi@gmail.com

Fwd: Your submission to BMC Infectious Diseases - INFD-D-19-02234R2

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Inga, Yohko

Thu, Jul 22, 2020, 9:18 AM

Forwarded Message

Subject: Your submission to BMC Infectious Diseases - INFD-D-19-02234R2
Date: 23 Jul 2020 07:08:49 +0400
From: BMC Infectious Diseases Editorial Office <ems@editorialmanager.com>
Reply-To: BMC Infectious Diseases Editorial Office <mailto:ems@editorialmanager.com>
To: Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R2

Potential therapeutic role of bone marrow-derived mesenchymal stem cells in acute lung injury caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice

Resti Yurhawati, Ph.D.; Muhammad Amin, Ph.D.; Fediq A Rantam, Ph.D.; Rima R Prasetyo, M.Sc.; Jeszy R Dewantari, B.Sc.; Atilia M Neehi, M.Sc.; Emmanuel D Poostarbo, Ph.D.; Laksmi Wutandarini, Ph.D.; Maria I Lusida, MD, Ph.D.; Soetjipto Soetjipto, MD, Ph.D.; Gatot Soegiarto, MD, Ph.D.; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu
BMC Infectious Diseases

Dear Dr. Shimizu,

Your manuscript "Potential therapeutic role of bone marrow-derived mesenchymal stem cells in acute lung injury caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice" (INFD-D-19-02234R2) has been assessed by the associate editor. A number of points have been raised which we believe would improve the manuscript and may allow a revised version to be published in BMC Infectious Diseases.

The report is below. Please also take a moment to check our website at <https://www.editorialmanager.com/inf> for any additional comments that were saved as attachments.

If you are able to fully address these points, we would encourage you to submit a revised manuscript to BMC Infectious Diseases. Once you have made the necessary corrections, please submit online at:

<https://www.editorialmanager.com/inf/>

If you have forgotten your password, please use the "Send Login Details" link on the login page at <https://www.editorialmanager.com/inf/>. For security reasons, your password will be reset.

Please include a cover letter with a point-by-point response to the comments, describing any additional experiments that were carried out and including a detailed rebuttal of any criticisms or requested revisions that you disagreed with. Please also ensure that all changes to the manuscript are indicated in the text by highlighting or using track changes.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 22 Aug 2020.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication. Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies.

To request a change in authorship, please download the "Request for change in authorship form" which can be found here - <http://www.biomedcentral.com/about/editorial/policies#authorship>.

Please note that incomplete forms will be rejected.

Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted. Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

I look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Karon Laurie
BMC Infectious Diseases
<https://bmcinfdis.biomedcentral.com/>

Technical Comments:

Editor Comments:

The interpretation of data must accurately represent the data presented. The discussion and results require modification to properly address the findings observed. In my view, use of a lethal dose of highly pathogenic influenza prevented discovery of further benefit from MSC administration. The morbidity and mortality is rapid, thus any regeneration or benefit from modification of cytokine dysregulation by MSCs could not be observed. Specific comments are listed below:

- The data show that lung injury as measured by lung alveolar protein and PaO2/FiO2 ratio, was reduced in MSC-treated group.
- The data also shows that cytokine expression was reduced in MSC-treated group.
- However, gross pathology is similar between MSC and mock treated in the pictures provided. Further, the immunohistochemistry pictures for images for SPC and Aqp5 levels are unconvincing as evidence of alveolar cell regeneration – reduction in loss would be more accurate.
- The immunofluorescence indicating the homing of MSCs to the lung is not clear. If MSCs home to sites of inflammation, it would be assumed that they would not home to lungs in un-infected mice. This control has not been performed. Please comment.
- MSC treatment does not affect virus shedding and animals still died. The virus quantification data is inconsistent as there is 200 x less infectious virus in the brain as compared to the lung for MSC-treated animals, yet the same amounts of vRNA copy when measured using molecular techniques. Please address this discrepancy.
- Test in the discussion requires modification: "For example, line 374 –Lung damage was not prevented by MSC treatment, rather it was reduced. Inflammatory markers were reduced." Furthermore, PaO2/FiO2 results indicate a mild hypoxia and the vRNA/infectious virus data are inconsistent. Reference 55 showed a reduction in influenza virus proliferation in the lung of hypoxic mice and of encephalitis in the brain. This was not observed in this study.

We operate a transparent peer review process for this journal where reviewer reports are published with the article but the reviewers are not named (unless they opt in to include their name).

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (<https://doi.org/10.1007/978-1-4939-9832-5>) and American Journal Experts (<https://ajed.com>) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language editors (ajed@www.ajed.com) or (ajed@nature.com) and our writing resources (<http://www.biomedcentral.com/getpublishedwriting-resources>). These cover common mistakes that occur when writing in English.

Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Infectious Diseases must contain a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (<https://bmcinfdis.biomedcentral.com/>).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files.

Please note that identifying/confidential patient data should not be shared.

Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons.

For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

-

Ethics approval and consent to participate

-

Consent to publish

-

Availability of data and materials

-

Competing interests

-

Funding

-

Authors' Contributions

-

Acknowledgements

Further information about our editorial policies can be found at the following links:

Ethical approval and consent:
<https://www.biomedcentral.com/about/editorial/policies#ethics>

Availability of data and materials section:
<https://www.biomedcentral.com/submissions/editorial-policies#availability-of-data-and-materials>

"Our flexible approach during the COVID-19 pandemic"

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springer.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/inf/links/amt7a9>). Please contact the publication office if you have any questions.

Compose

Inbox 4,860

Starred

Snoozed

Important

Sent

Meet

New meeting

Join a meeting

Hangouts

Resti +

No recent chats

Start a new chat

Fwd: Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R3

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yohko

Sun, Aug 23, 2020, 1:33 AM

Dear Dr. Resti,

Early this morning, I finished revising figures and successfully uploaded on time the revised manuscript. Attached the PDF file of the manuscript R3.

Thank you,
Kazufumi Shimizu

----- Forwarded Message -----

Subject:Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R3
Date:22 Aug 2020 18:26:25 -0400
From:BMC Infectious Diseases Editorial Office <em@editorialmanager.com>
Reply-To:BMC Infectious Diseases Editorial Office <marielette.costoy@springer.com>
To:Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R3

Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice

Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc; Jezy R Dewantari, B.Sc; Aldise M Natri, M.Sc; Emmanuel D Poetranto, Ph.D; Laksmi Wulandari1, Ph.D; Maria I Lusida, MD, Ph.D; Soetjipto Soetjipto, MD, Ph.D; Gatot Soegiarto, MD, Ph.D; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu
BMC Infectious Diseases

Dear Dr. Shimizu,

Thank you for the revised version of your manuscript 'Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice' submitted to BMC Infectious Diseases.

You may check the status of your manuscript at any time by accessing the following website:

<https://www.editorialmanager.com/inf/>

If you have forgotten your password, please use the 'Send Login Details' link on the login page at <https://www.editorialmanager.com/inf/>. For security reasons, your password will be reset.

We will inform you of the Editor's decision as soon as possible.

Best wishes,

Editorial Office
BMC Infectious Diseases
<https://bmcinfectdis.biomedcentral.com/>

****Our flexible approach during the COVID-19 pandemic****

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/inf/login.asp?a=r>). Please contact the publication office if you have any questions.



shimizu.kazufumi@gmail.com

Compose

Inbox 4,162

Starred

Snoozed

Important

Sent

Meet

New meeting

Join a meeting

Hangouts

Resti -

No recent chats

20 of many

Fwd: Your submission to BMC Infectious Diseases - INF-D-19-02234R3

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yshko

Mon, Sep 14, 2020, 11:05 PM

Dear Dr. Resti,

Fortunately, the decision is "Acceptable with minor revisions". We can easily revise it.

With regards,
Kazufumi Shimizu

----- Forwarded Message -----
Subject:Your submission to BMC Infectious Diseases - INF-D-19-02234R3
Date:15 Sep 2020 01:48:03 -0400
From:BMC Infectious Diseases Editorial Office <em@editorialmanager.com>
Reply-To:BMC Infectious Diseases Editorial Office <cardio.depedua@scipostsignature.com>
To:Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INF-D-19-02234R3
Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice

Resti Yudhawati, Ph.D.; Muhamad Amin, Ph.D.; Fedik A Faridani, Ph.D.; Rima R Prasetya, M.Sc.; Jazzy R Dewanti, B.Sc.; Akhse M Nastri, M.Sc.; Emmanuel D Poozanto, Ph.D.; Lakami Wulandari, Ph.D.; Maria I Lusida, MD, Ph.D.; Soetjipto Soetjipto, MD, Ph.D.; Galeri Soegarto, MD, Ph.D.; Yuhiko K Shimizu; Yasuko Mori; Kazufumi Shimizu
BMC Infectious Diseases

Dear Dr. Shimizu,

Your manuscript "Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice" (INF-D-19-02234R3) has been assessed by our reviewers. Based on these reports, and my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for publication in BMC Infectious Diseases, once you have carried out some essential revisions suggested by our reviewers.

Their reports, together with any other comments, are below. Please also take a moment to check our website at <http://www.editorialmanager.com/inf> for any additional comments that were saved as attachments.

If you are able to fully address these points, we would encourage you to submit a revised manuscript to BMC Infectious Diseases. Once you have made the necessary corrections, please submit a revised manuscript online at:

<http://www.editorialmanager.com/inf/>

If you have forgotten your password, please use the "Send Login Details" link on the login page at <http://www.editorialmanager.com/inf/>. For security reasons, your password will be reset.

We request that a point-by-point response letter accompanies your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing what amendments have been made to the manuscript text and where these can be found (e.g. Methods section, line 12, page 5). If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 29 Sep 2020.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication. Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies.

To request a change in authorship, please download the "Request for change in authorship form" which can be found here - <http://www.biomedcentral.com/about/editorial/policies#authorship>. Please note that incomplete forms will be rejected.

Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted. Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Karen Laurie
BMC Infectious Diseases
<http://bit.ly/infidms.biomedcentral.com/>

Technical Comments:

Editor Comments:

Thank you for addressing the comments.

Minor comments:

Figure 1 - please indicate the # of mice killed at the end of the study (4 per group?) for clarity for the reader

Line 359 should read: MSCs did not reduce viral proliferation in mice with the A/H5N1 lethal infection.

The authors clarified the increase in virus replication in the brain of MSC-treated mice. Is there a hypothesis as to why this occurred?

We operate a transparent peer review process for this journal where reviewer reports are published with the article but the reviewers are not named (unless they opt in to include their name).

Reviewer reports:

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (http://bit.ly/nres_bs) and American Journal Experts (http://bit.ly/AJE_BS) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial (<https://www.springer.com/author-services/authorandresearcherhelp/englishtutorial>) and our Writing resources (<http://www.biomedcentral.com/published/writing-resources>). These cover common mistakes that occur when writing in English.

Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Infectious Diseases must contain a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (<http://www.biomedcentral.com/about/editorial/policies>).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the "Availability of data and materials" section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files.

Please note that identifying/confidential patient data should not be shared.

Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons.

For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

-

Ethics approval and consent to participate

-

Consent to publish

-

Availability of data and materials

-

Competing interests

-

Funding

-

Authors' Contributions

-

Acknowledgements

Further information about our editorial policies can be found at the following links:

Ethical approval and consent:
<http://www.biomedcentral.com/about/editorial/policies#Ethics>

Availability of data and materials section:
<http://www.biomedcentral.com/submission/editorial-policies#availability-of-data-and-materials>

"Our flexible approach during the COVID-19 pandemic"

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <http://www.springer.com/author-services/authorandresearcherhelp/privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <http://www.editorialmanager.com/inf/login.asp?ser>). Please contact the publication office if you have any questions.

Compose

- Inbox 4,860
- Starred
- Snoozed
- Important
- Sent

- Meet
- New meeting
 - Join a meeting

- Hangouts
- Resti -
 - No recent chats
 - Start a new one

Fwd: Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R4

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yohko

Thu, Sep 17, 2020, 3:08 AM

----- Forwarded Message -----

Subject:Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R4
Date:17 Sep 2020 06:04:08 -0400
From:BMC Infectious Diseases Editorial Office <em@editorialmanager.com>
Reply-To:BMC Infectious Diseases Editorial Office <jeanelle.depadua@springernature.com>
To:Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R4
 Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice
 Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc; Jezzy R Dewantari, B.Sc; Aldise M Nastri, M.Sc; Emmanuel D Poetranto, Ph.D; Laksmi Wulandari1, Ph.D; Maria I Lusida, MD, Ph.D; Soetjipto Soetjipto, MD, Ph.D; Gatot Soegiarto, MD. Ph.D; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu
 BMC Infectious Diseases

Dear Dr. Shimizu,

Thank you for the revised version of your manuscript 'Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice' submitted to BMC Infectious Diseases.

You may check the status of your manuscript at any time by accessing the following website:

<https://www.editorialmanager.com/infd/>

If you have forgotten your password, please use the 'Send Login Details' link on the login page at <https://www.editorialmanager.com/infd/>. For security reasons, your password will be reset.

We will inform you of the Editor's decision as soon as possible.

Best wishes,

Editorial Office
 BMC Infectious Diseases
<https://bmcinfectdis.biomedcentral.com/>

****Our flexible approach during the COVID-19 pandemic****

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/infd/login.asp?a=r>). Please contact the publication office if you have any questions.



- Reply
- Reply all
- Forward

Compose

Inbox 4,860

Starred
 Snoozed
 Important
 Sent

Meet

New meeting
 Join a meeting

Hangouts

Resti +

No recent chats

Start a new one

Fwd: Your submission to BMC Infectious Diseases - INFD-D-19-02234R4

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yohko

Fri, Oct 9, 2020, 1:52 PM

Almost, only editorial comments.

Kazufumi Shimizu

----- Forwarded Message -----

Subject:Your submission to BMC Infectious Diseases - INFD-D-19-02234R4
Date:9 Oct 2020 11:08:21 -0400
From:BMC Infectious Diseases Editorial Office <em@editorialmanager.com>
Reply-To:BMC Infectious Diseases Editorial Office <jeanelle.depadua@springernature.com>
To:Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R4

Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice

Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc; Jezzy R Dewantari, B.Sc; Aldise M Nastri, M.Sc; Emmanuel D Poetranto, Ph.D; Laksmi Wulandari1, Ph.D; Maria I Lusida, MD, Ph.D; Soetjipto Soetjipto, MD, Ph.D; Gatot Soegiarto, MD, Ph.D; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu
BMC Infectious Diseases

Dear Dr. Shimizu,

Your manuscript "Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice" (INFD-D-19-02234R4) has been assessed by our reviewers. Based on these reports, and my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for publication in BMC Infectious Diseases, once you have carried out some essential revisions suggested by our reviewers.

Their reports, together with any other comments, are below. Please also take a moment to check our website at <https://www.editorialmanager.com/infd/> for any additional comments that were saved as attachments.

If you are able to fully address these points, we would encourage you to submit a revised manuscript to BMC Infectious Diseases. Once you have made the necessary corrections, please submit a revised manuscript online at:

<https://www.editorialmanager.com/infd/>

If you have forgotten your password, please use the 'Send Login Details' link on the login page at <https://www.editorialmanager.com/infd/>. For security reasons, your password will be reset.

We request that a point-by-point response letter accompanies your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing what amendments have been made to the manuscript text and where these can be found (e.g. Methods section, line 12, page 5). If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 23 Oct 2020.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication. Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies.

To request a change in authorship, please download the 'Request for change in authorship form' which can be found here - <http://www.biomedcentral.com/about/editorialpolicies#authorship>.

Please note that incomplete forms will be rejected.

Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted.

Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,
Taylor Hayes
on behalf of Sarah Gray
BMC Infectious Diseases
<https://bmcinfectdis.biomedcentral.com/>

Editor Comments:

1. Please indicate the authors Soetjipto Soetjipto and Gatot Soegiarto separately on your title page. 2. Please clearly indicate one corresponding author on your title page.

3. Please note the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript should be declared in the Funding section

4. Please consider the list of authors as it currently stands with reference to our guidelines regarding qualification for authorship (<http://www.biomedcentral.com/submissions/editorial-policies#authorship>).

Currently, the contributions of authors Jezzy R Dewantari, Aldise M Nastri, Laksmi Wulandari, Gatot Soegiarto, Soetjipto Soetjipto, Maria I Lusida do not automatically qualify them for authorship. In the section "Authors' contributions", please provide further clarifications on their contributions, and see our guidelines for authorship below.

An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. Authors are expected to fulfil the criteria below (adapted from McNutt et al., Proceedings of the National Academy of Sciences, Feb 2018, 201715374; DOI: 10.1073/pnas.1715374115; licensed under CC BY 4.0):

Each author is expected to have made substantial contributions to the conception OR design of the work; OR the acquisition, analysis, OR interpretation of data; OR the creation of new software used in the work; OR have drafted the work or substantively revised it

AND to have approved the submitted version (and any substantially modified version that involves the author's contribution to the study);

AND to have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Acquisition of funding, collection of data or general supervision of the research group, alone, does not usually justify authorship.

If these guidelines are not met, we would request the following change of authorship form be filled out and sent to our Editorial Office

(BMCSeriesEditorial@biomedcentral.com) - <https://www.biomedcentral.com/submissions/editorial-policies#authorship>

Anyone who contributed towards the article who does not meet the criteria for authorship can be acknowledged in the 'Acknowledgements' section.

5. Please remove your ARRIVE checklist. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Additional files should remain uploaded as separate files. Please ensure that all figures, tables and additional/supplementary files are cited within the text.

We operate a transparent peer review process for this journal where reviewer reports are published with the article but the reviewers are not named (unless they opt in to include their name).

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (http://bit.ly/NRES_BS) and American Journal Experts (http://bit.ly/AJE_BS) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial (<https://www.springer.com/gb/authors-editors/authorandreviewertutorials/writinginenglish>) and our Writing resources (<http://www.biomedcentral.com/getpublished/writing-resources>). These cover common mistakes that occur when writing in English.

----- Editorial Policies -----

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Infectious Diseases must contain a Declarations section which includes the mandatory sub-sections listed below.

Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (<https://bmcinfectdis.biomedcentral.com/>).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found.

We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files.

Please note that identifying/confidential patient data should not be shared.

Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons.

For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

-

Ethics approval and consent to participate

-

Consent to publish

-

Availability of data and materials

-

Competing interests

-

Funding

-

Authors' Contributions

-

Acknowledgements

Further information about our editorial policies can be found at the following links:

Ethical approval and consent:

<http://www.biomedcentral.com/about/editorialpolicies#Ethics>

Availability of data and materials section:

<http://www.biomedcentral.com/submissions/editorial-policies#availabilityofdataandmaterials>



****Our flexible approach during the COVID-19 pandemic****

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/infd/login.asp?a=r>). Please contact the publication office if you have any questions.

Compose

Inbox 4,860

Starred

Snoozed

Important

Sent

Meet

New meeting

Join a meeting

Hangouts

Resti

No recent chats

Start a new one

Fwd: Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R5

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yohko

Mon, Oct 12, 2020, 10:38 AM

----- Forwarded Message -----

Subject:Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R5**Date:**12 Oct 2020 13:31:15 -0400**From:**BMC Infectious Diseases Editorial Office <em@editorialmanager.com>**Reply-To:**BMC Infectious Diseases Editorial Office <jeanelle.depdua@springernature.com>**To:**Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R5

Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice

Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc; Jezzy R Dewantari, B.Sc; Aldise M Nastri, M.Sc; Emmanuel D Poetranto, Ph.D; Laksmi Wulandari1, Ph.D; Maria I Lusida, MD, Ph.D; Soetjpto Koesnowidagdo, MD, Ph.D; Gatot Soegiarto, MD, Ph.D; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu

BMC Infectious Diseases

Dear Dr. Shimizu,

Thank you for the revised version of your manuscript 'Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice' submitted to BMC Infectious Diseases.

You may check the status of your manuscript at any time by accessing the following website:

<https://www.editorialmanager.com/inf/>

If you have forgotten your password, please use the 'Send Login Details' link on the login page at <https://www.editorialmanager.com/inf/>. For security reasons, your password will be reset.

We will inform you of the Editor's decision as soon as possible.

Best wishes,

Editorial Office
BMC Infectious Diseases
<https://bmcinfectdis.biomedcentral.com/>

"Our flexible approach during the COVID-19 pandemic"

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/inf/login.asp?a=r>). Please contact the publication office if you have any questions.



Compose

Inbox 4,860

Starred
Snoozed
Important
Sent

Meet

New meeting
Join a meeting

Hangouts

Resti +

No recent chats

Start a new one

Fwd: Your submission to BMC Infectious Diseases - INFD-D-19-02234R5

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yohko

Wed, Oct 14, 2020, 2:48 AM

Euthanasia again!!!

Maybe we should describe more detail.

----- Forwarded Message -----

Subject: Your submission to BMC Infectious Diseases - INFD-D-19-02234R5**Date:** 14 Oct 2020 05:28:16 -0400**From:** BMC Infectious Diseases Editorial Office <em@editorialmanager.com>**Reply-To:** BMC Infectious Diseases Editorial Office <jeanelle.depadua@springernature.com>**To:** Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R5

Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice

Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc; Jezy R Dewantari, B.Sc; Aldise M Nastri, M.Sc; Emmanuel D Poetranto, Ph.D; Laksmi Wulandari1, Ph.D; Maria I Lusida, MD, Ph.D; Soetjipto Koesnowidagdo, MD, Ph.D; Gatot Soegiarto, MD, Ph.D; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu

BMC Infectious Diseases

Dear Dr. Shimizu,

Your manuscript "Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice" (INFD-D-19-02234R5) has been assessed by our reviewers. Based on these reports, and my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for publication in BMC Infectious Diseases, once you have carried out some essential revisions.

Once you have made the necessary corrections, please submit a revised manuscript online at:

<https://www.editorialmanager.com/infd/>

If you have forgotten your password, please use the 'Send Login Details' link on the login page at <https://www.editorialmanager.com/infd/>. For security reasons, your password will be reset.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 17 Oct 2020.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication. Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies.

To request a change in authorship, please download the 'Request for change in authorship form' which can be found here -

<http://www.biomedcentral.com/about/editorialpolicies#authorship>.

Please note that incomplete forms will be rejected.

Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted.

Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Sarah Gray
BMC Infectious Diseases
<https://bmcinfectdis.biomedcentral.com/>

Editor Comments:

Thank you for amending your manuscript according to our requests and for providing further clarification. However, there are a few minor revisions that are necessary before we can accept the manuscript for publication, please see below.

1. Euthanasia Dosage

Please clarify your euthanasia/sacrifice methods, including injection dosages if applicable, methods used and rationale etc.

Please try to be as detailed as possible.

Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Infectious Diseases must contain a Declarations section which includes the mandatory sub-sections listed below.

Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (<https://bmcinfectdis.biomedcentral.com/>).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files.

Please note that identifying/confidential patient data should not be shared.

Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons.

For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

-

Ethics approval and consent to participate

-

Consent to publish

-

Availability of data and materials

-

Competing interests

-

Funding

-

Authors' Contributions

-

Acknowledgements

Further information about our editorial policies can be found at the following links:

Ethical approval and consent:

<http://www.biomedcentral.com/about/editorialpolicies#Ethics>

Availability of data and materials section:

<http://www.biomedcentral.com/submissions/editorial-policies#availability-of+data+and+materials>

****Our flexible approach during the COVID-19 pandemic****

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/infid/login.asp?a=r>). Please contact the publication office if you have any questions.

Compose

- Inbox 4,860
- Starred
- Snoozed
- Important
- Sent

- Meet
- New meeting
 - Join a meeting

- Hangouts
- Resti -
 - No recent chats
 - Start a new one

Fwd: Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R6

Shimizu Kazufumi <shimizu.kazufumi@gmail.com>
to me, Yohko

Wed, Oct 14, 2020, 9:01 AM

----- Forwarded Message -----

Subject:Confirmation of revised submission to BMC Infectious Diseases - INFD-D-19-02234R6
Date:14 Oct 2020 11:54:06 -0400
From:BMC Infectious Diseases Editorial Office <em@editorialmanager.com>
Reply-To:BMC Infectious Diseases Editorial Office <jeanelle.depadua@springernature.com>
To:Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R6
 Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice
 Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc; Jezzy R Dewantari, B.Sc; Aldise M Nastri, M.Sc; Emmanuel D Poetranto, Ph.D; Laksmi Wulandari1, Ph.D; Maria I Lusida, MD, Ph.D; Soetjipto Koesnowidagdo, MD, Ph.D; Gatot Soegiarto, MD, Ph.D; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu
 BMC Infectious Diseases

Dear Dr. Shimizu,

Thank you for the revised version of your manuscript 'Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice' submitted to BMC Infectious Diseases.

You may check the status of your manuscript at any time by accessing the following website:

<https://www.editorialmanager.com/infd/>

If you have forgotten your password, please use the 'Send Login Details' link on the login page at <https://www.editorialmanager.com/infd/>. For security reasons, your password will be reset.

We will inform you of the Editor's decision as soon as possible.

Best wishes,

Editorial Office
 BMC Infectious Diseases
<https://bmcinfectdis.biomedcentral.com/>

****Our flexible approach during the COVID-19 pandemic****

If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/infd/login.asp?a=r>). Please contact the publication office if you have any questions.



Reply Reply all Forward

Compose button and sidebar navigation including Inbox (4,860), Starred, Snoozed, Important, Sent, Meet, and Hangouts.

Fwd: Decision on your Submission to BMC Infectious Diseases - INFD-D-19-02234R6

Shimizu Kazufumi <shimizu.kazufumi@gmail.com> Thu, Oct 15, 2020, 4:19 AM

Dear Dr. Resti and Colleagues,

Our manuscript is finally accepted by BMC Infectious Diseases.

With best regards,
Kazufumi Shimizu

----- Forwarded Message -----

Subject: Decision on your Submission to BMC Infectious Diseases - INFD-D-19-02234R6
Date: 15 Oct 2020 05:51:13 -0400
From: BMC Infectious Diseases Editorial Office <em@editorialmanager.com>
Reply-To: BMC Infectious Diseases Editorial Office <jeanelle.depadua@springernature.com>
To: Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

INFD-D-19-02234R6
Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice
Resti Yudhawati, Ph.D.; Muhammad Amin, Ph.D.; Fedik A Rantam, Ph.D.; Rima R Prasetya, M.Sc.; Jezzy R Dewantari, B.Sc.; Aldise M Nastri, M.Sc.; Emmanuel D Postranto, Ph.D.; Laksmi Wulandari 1, Ph.D.; Maria I Lusida, MD, Ph.D.; Soetjipto Koesnowidagdo, MD, Ph.D.; Gatot Soegiarto, MD, Ph.D.; Yohko K Shimizu; Yasuko Mori; Kazufumi Shimizu
BMC Infectious Diseases

Dear Dr. Shimizu,

I am pleased to inform you that your manuscript "Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice" (INFD-D-19-02234R6) has been accepted for publication in BMC Infectious Diseases.

If any final comments have been submitted from our reviewers or editors, these can be found at the foot of this email for your consideration.

Before publication, our production team will also check the format of your manuscript to ensure that it conforms to the standards of the journal. They will be in touch shortly to request any necessary changes, or to confirm that none are needed.

Articles in this journal may be held for a short period of time prior to publication.
If you have any concerns please contact the journal.

Please do not hesitate to contact us if you have any questions regarding your manuscript and I hope that you will consider BMC Infectious Diseases again in the future.

If you wish to co-submit a data note to be published in BMC Research Notes (<https://bmcresearchnotes.biomedcentral.com/about/introducing-data-notes>) you can do so by visiting our submission portal <http://www.editorialmanager.com/resn/>. Data notes support open data (<https://www.springernature.com/go/open-research/open-data>) and help authors to comply with funder policies on data sharing. Please note that this additional service is entirely optional.

Best wishes,

Stuart Weir on behalf of,
Sarah Gray
BMC Infectious Diseases
<https://hmcinfectdis.biomedcentral.com/>

Comments:

--
Please also take a moment to check our website at <https://bmcinfectdis.biomedcentral.com/>.

We operate a transparent peer review process for this journal where reviewer reports are published with the article but the reviewers are not named (unless they opt in to include their name).

Our flexible approach during the COVID-19 pandemic
If you need more time at any stage of the peer-review process, please do let us know. While our systems will continue to remind you of the original timelines, we aim to be as flexible as possible during the current pandemic.

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at <https://www.springernature.com/production-privacy-policy>. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/info/login.asp?a=1>). Please contact the publication office if you have any questions.



Compose

- Inbox 4,860
- Starred
- Snoozed
- Important
- Sent

- Meet
- New meeting
- Join a meeting

- Hangouts
- Resti +
- No recent chats
- Start a new one

4 of many < >

Fwd: INFD-D-19-02234: Publishing your article – information required

Shimizu Kazufumi <shimizu.kazufumi@gmail.com> Wed, Nov 11, 2020, 10:07 PM ☆ ↶ ⋮
 to me, Yohko ▾

----- Forwarded Message -----
Subject:INFD-D-19-02234: Publishing your article – information required
Date:Wed, 11 Nov 2020 08:30:01 +0000
From:BioMed Central Customer Services <info@biomedcentral.com>
To:Kazufumi Shimizu <shimizu.kazufumi@gmail.com>

Dear Kazufumi Shimizu,

Congratulations on the acceptance of your article, INFD-D-19-02234, in BMC Infectious Diseases. Our Production team now has your manuscript and will be in touch with you shortly.

As BMC Infectious Diseases is an open access journal, all authors are required to pay an article-processing charge (APC).

However, please note that:

- Your APC may be covered in full or in part by an institutional open access agreement
- If you have already been granted a discount or waiver, you may be eligible for further funding of your APC

To check your eligibility, please click on the following link to confirm your institutional affiliation:
<https://payment.biomedcentral.com/eligibility/4532795022025578>

Should you have any questions about the publication of your manuscript, please do get in touch.

Best wishes,

Open Research Support
Email: ORSupport@springemature.com

Thanks a lot. Done. Noted with thanks.

Reply Reply all Forward